1-hydroxyaklavinone is a **natural product** with a **complex chemical structure**. It is a **quinone** derived from **aklavinone**, which is a **highly potent antitumor antibiotic**.
Here's why it is important for research:
**1. Potential Anticancer Activity:** 1-hydroxyaklavinone exhibits significant **cytotoxic activity against various cancer cell lines**. This property makes it a promising lead compound for the development of new anticancer drugs.
**2. Mechanism of Action:** Research on 1-hydroxyaklavinone has shed light on the **mechanisms of action of anthracycline antibiotics**, a class of chemotherapy drugs. It has been shown to **intercalate into DNA**, **inhibit DNA replication and transcription**, and **induce apoptosis**. This knowledge is crucial for understanding how these drugs work and designing new ones with improved efficacy and reduced side effects.
**3. Structure-Activity Relationship:** 1-hydroxyaklavinone's complex structure has made it a valuable tool for studying the **relationship between chemical structure and biological activity**. By modifying its structure, researchers can investigate how changes in the molecule affect its potency, selectivity, and pharmacokinetic properties. This knowledge can then be used to design even more effective antitumor agents.
**4. Bioavailability:** The study of 1-hydroxyaklavinone has led to the development of novel **drug delivery systems** to improve its bioavailability and reduce its toxicity. This is an important step in translating promising anticancer agents from the lab to the clinic.
**5. Synthetic Methods:** Research on 1-hydroxyaklavinone has also advanced the development of **synthetic methods** for producing complex natural products. These methods can be used to create new analogs of 1-hydroxyaklavinone with potentially improved properties, as well as other valuable pharmaceuticals.
Overall, 1-hydroxyaklavinone is a fascinating molecule with a wide range of potential applications in cancer research and drug development. Its study has provided valuable insights into the mechanisms of action of anthracycline antibiotics, facilitated the development of new synthetic methods, and led to promising new approaches for drug delivery.
epsilon-pyrromycinone: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 159908 |
| CHEMBL ID | 3039086 |
| CHEBI ID | 108590 |
| MeSH ID | M0053583 |
| Synonym |
|---|
| BSPBIO_002709 |
| SDCCGMLS-0066382.P001 |
| 1-naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,4,5,7,10-pentahydroxy-6,11-dioxo-, methyl ester, (1r,2r,4s)- |
| epsilon-pyrromycinone |
| ma 144d2 |
| nsc 114778 |
| rutilantinone |
| 1-naphthacenecarboxylic acid, 1,2,3,4,6,11-hexahydro-2-ethyl-2,4,5,7,10-pentahydroxy-6,11-dioxo-, methyl ester, (1r,2r,4s)- |
| rutilantinon |
| SPECTRUM_000795 |
| SPECTRUM5_000284 |
| NCGC00178516-01 |
| KBIO2_003843 |
| KBIO2_006411 |
| KBIO2_001275 |
| KBIO3_002209 |
| KBIOSS_001275 |
| KBIOGR_001904 |
| SPBIO_000524 |
| SPECTRUM4_001432 |
| SPECTRUM2_000452 |
| SPECTRUM3_001155 |
| SPECTRUM201606 |
| CHEBI:108590 |
| HMS1923A07 |
| galirubine |
| 1-hydroxyaklavinone |
| CCG-38694 |
| CHEMBL3039086 |
| Q27187513 |
| (1r,2r,4s)-2-ethyl-2,4,5,7,10-pentahydroxy-6,11-dioxo-3,4-dihydro-1h-tetracene-1-carboxylic acid methyl ester |
| sr-05000002666 |
| SR-05000002666-1 |
| RWCVSDKDFSVZNF-KRYGIPSASA-N |
| epsilon-pyrromy-cinone |
| BRD-K11258719-001-03-2 |
| Class | Description |
|---|---|
| tetracenes | Compounds containing a tetracene skeleton. |
| p-quinones | A quinone in which the two oxo groups of the quinone are located para to each other on the 6-membered quinonoid ring. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID977602 | Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID977599 | Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID1159550 | Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening | 2015 | Nature cell biology, Nov, Volume: 17, Issue:11 | 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.58) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 2 (20.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||